Latest Abaxis Inc (ABAX) Headlines
Updated Research Report on Abaxis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:20PM CDT
On Mar 11, 2014, we issued an updated research report on Abaxis.
Abaxis to Participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference
PR Newswire - Wed Mar 12, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Don Wood, Chief Operations Officer, will participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference on Tuesday, March 18, 2014.
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abaxis, Inc. to Present at the Sidoti & Company Eighteenth Annual Institutional Investor Forum
PR Newswire - Tue Mar 11, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Sidoti & Company Eighteenth Annual Institutional Investor Forum on Tuesday, March 18, 2014 at 10:00 a.m. ET. The conference will be held at the Grand Hyatt New York in New York City.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Monday
Abaxis, Inc. to Present at the Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Thu Feb 27, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Raymond James 35th Annual Institutional Investors Conference on Monday, March 3, 2014 at 10:25 a.m. ET. The conference will be held at the JW Marriott Grande Lakes Hotel in Orlando, Florida.
This Company's "Dismal" Performance Masks Excellent Opportunity
John Leonard, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
Abaxis fell sharply after reporting disappointing results last month. However the recent recovery suggests the market is beginning to realize that the cause for the "dismal" results (the CEO's words) is most likely a one-off occurrence rather...
Should You Get Rid of Abaxis (ABAX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:30AM CST
It is time to get rid of Abaxis, as it has witnessed a significant price decline in the past four weeks and has seen negative earnings estimate revisions
Abaxis Awarded Veterinary Services Central Fund (VSCF) Contract for Veterinary Diagnostic Laboratory Services from the Department of the Army
PR Newswire - Thu Feb 06, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets worldwide and providing reference lab services to the veterinary and research markets in the United States, announced today that the Department of the Army, Army NAF Contracting has awarded the Company, a contract to provide veterinary diagnostic laboratory services to the Veterinary Services Central Fund (VSCF). This contract provides point-of-care laboratory diagnostic instruments and reagents, as well as reference laboratory services through Abaxis Veterinary Reference Laboratories (AVRL) to approximately 118 Army veterinary activities within the Continental United States (CONUS) and Outside the Continental United States (OCONUS). The period of performance under this contract is for one year, effective immediately with options for four additional one-year periods with maximum order/quantity limitations of $3 million per year.
Abaxis Enters Oversold Territory (ABAX)
MarketNewsVideo.com - Fri Jan 31, 11:12AM CST
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
Abaxis Misses Q3 Earnings & Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 11:10AM CST
Abaxis reported a disappointing third-quarter fiscal 2014 with earnings per share of 14 cents missing both the Zacks Consensus Estimate and the year-ago earnings of 22 cents by a massive 31.8%.
Abaxis slumps as 1Q totals fall short of estimates
AP - Fri Jan 31, 10:10AM CST
NEW YORK (AP) — Shares of Abaxis fell Friday after the blood analysis systems developer posted disappointing third-quarter results, saying orders didn't live up to its expectations.
Downgrade Alert for Abaxis (ABAX)
Comtex SmarTrend(R) - Fri Jan 31, 7:12AM CST
Abaxis (NASDAQ:ABAX) was downgraded from Hold to Sell at Feltl today. The stock closed yesterday at $38.04 on volume of 892,000 shares, above average daily volume of 167,000. Over the past year, Abaxis has traded in a range of $32.11 to $51.84 and closed yesterday at $38.04, 18% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.0%.
Abaxis Inc posts lower net income of USD3.2m for Q3 fiscal 2014
M2 - Fri Jan 31, 5:39AM CST
Medical products company Abaxis Inc (NasdaqGS:ABAX) announced on Thursday its net income of USD3.2m for the third fiscal quarter ended 31 December 2013.
Abaxis Reports Financial Performance For The Third Quarter Of Fiscal 2014
PR Newswire - Thu Jan 30, 3:00PM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2013.
Axion Health Welcomes New Board Member
PR Newswire - Thu Jan 23, 7:00AM CST
Axion Health appoints Ian Ziskin to its Board of Directors. Mr. Ziskin recently accepted an appointment to the Axion Health Board of Directors. Ian is president of EXec EXcel Group LLC, a coaching and consulting firm he founded in 2010 following a highly successful 28-year corporate business career. He also serves as an Executive in Residence with the Center for Effective Organizations (CEO), Marshall School of Business, University of Southern California and as an Executive Advisor to Executive Networks, Inc.
Abaxis To Report Third Quarter Fiscal Year 2014 Financial Results Thursday, January 30, 2014
PR Newswire - Wed Jan 22, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, has scheduled a conference call to discuss its financial results for the third quarter fiscal year 2014, ended December 31, 2013. The call will be at 4:15 p.m. ET on Thursday, January 30, 2014. The Company will report financial results for the third quarter fiscal year 2014 after the market closes on Thursday, January 30, 2014.
Updated Research Report on Abaxis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:20PM CDT
On Mar 11, 2014, we issued an updated research report on Abaxis.
Abaxis to Participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference
PR Newswire - Wed Mar 12, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Don Wood, Chief Operations Officer, will participate in BTIG's Inaugural Snowbird Medical Technology and Diagnostics Conference on Tuesday, March 18, 2014.
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abaxis, Inc. to Present at the Sidoti & Company Eighteenth Annual Institutional Investor Forum
PR Newswire - Tue Mar 11, 7:00AM CDT
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Sidoti & Company Eighteenth Annual Institutional Investor Forum on Tuesday, March 18, 2014 at 10:00 a.m. ET. The conference will be held at the Grand Hyatt New York in New York City.
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Monday
Abaxis, Inc. to Present at the Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Thu Feb 27, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer , will present at the Raymond James 35th Annual Institutional Investors Conference on Monday, March 3, 2014 at 10:25 a.m. ET. The conference will be held at the JW Marriott Grande Lakes Hotel in Orlando, Florida.
This Company's "Dismal" Performance Masks Excellent Opportunity
John Leonard, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
Abaxis fell sharply after reporting disappointing results last month. However the recent recovery suggests the market is beginning to realize that the cause for the "dismal" results (the CEO's words) is most likely a one-off occurrence rather...
Should You Get Rid of Abaxis (ABAX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:30AM CST
It is time to get rid of Abaxis, as it has witnessed a significant price decline in the past four weeks and has seen negative earnings estimate revisions
Abaxis Awarded Veterinary Services Central Fund (VSCF) Contract for Veterinary Diagnostic Laboratory Services from the Department of the Army
PR Newswire - Thu Feb 06, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets worldwide and providing reference lab services to the veterinary and research markets in the United States, announced today that the Department of the Army, Army NAF Contracting has awarded the Company, a contract to provide veterinary diagnostic laboratory services to the Veterinary Services Central Fund (VSCF). This contract provides point-of-care laboratory diagnostic instruments and reagents, as well as reference laboratory services through Abaxis Veterinary Reference Laboratories (AVRL) to approximately 118 Army veterinary activities within the Continental United States (CONUS) and Outside the Continental United States (OCONUS). The period of performance under this contract is for one year, effective immediately with options for four additional one-year periods with maximum order/quantity limitations of $3 million per year.
Abaxis Enters Oversold Territory (ABAX)
MarketNewsVideo.com - Fri Jan 31, 11:12AM CST
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
Abaxis Misses Q3 Earnings & Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 11:10AM CST
Abaxis reported a disappointing third-quarter fiscal 2014 with earnings per share of 14 cents missing both the Zacks Consensus Estimate and the year-ago earnings of 22 cents by a massive 31.8%.
Abaxis slumps as 1Q totals fall short of estimates
AP - Fri Jan 31, 10:10AM CST
NEW YORK (AP) — Shares of Abaxis fell Friday after the blood analysis systems developer posted disappointing third-quarter results, saying orders didn't live up to its expectations.
Downgrade Alert for Abaxis (ABAX)
Comtex SmarTrend(R) - Fri Jan 31, 7:12AM CST
Abaxis (NASDAQ:ABAX) was downgraded from Hold to Sell at Feltl today. The stock closed yesterday at $38.04 on volume of 892,000 shares, above average daily volume of 167,000. Over the past year, Abaxis has traded in a range of $32.11 to $51.84 and closed yesterday at $38.04, 18% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.0%.
Abaxis Inc posts lower net income of USD3.2m for Q3 fiscal 2014
M2 - Fri Jan 31, 5:39AM CST
Medical products company Abaxis Inc (NasdaqGS:ABAX) announced on Thursday its net income of USD3.2m for the third fiscal quarter ended 31 December 2013.
Abaxis Reports Financial Performance For The Third Quarter Of Fiscal 2014
PR Newswire - Thu Jan 30, 3:00PM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2013.
Axion Health Welcomes New Board Member
PR Newswire - Thu Jan 23, 7:00AM CST
Axion Health appoints Ian Ziskin to its Board of Directors. Mr. Ziskin recently accepted an appointment to the Axion Health Board of Directors. Ian is president of EXec EXcel Group LLC, a coaching and consulting firm he founded in 2010 following a highly successful 28-year corporate business career. He also serves as an Executive in Residence with the Center for Effective Organizations (CEO), Marshall School of Business, University of Southern California and as an Executive Advisor to Executive Networks, Inc.
Abaxis To Report Third Quarter Fiscal Year 2014 Financial Results Thursday, January 30, 2014
PR Newswire - Wed Jan 22, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, has scheduled a conference call to discuss its financial results for the third quarter fiscal year 2014, ended December 31, 2013. The call will be at 4:15 p.m. ET on Thursday, January 30, 2014. The Company will report financial results for the third quarter fiscal year 2014 after the market closes on Thursday, January 30, 2014.
